Certolizumab pegol (CDP870) for rheumatoid arthritis in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Ruiz Garcia, Vicente ^a   Jobanputra, Paresh ^b   Burls, Amanda ^c   Cabello, Juan B ^d   Vela Casasempere, Paloma ^d   Bort Marti, Sylvia ^e   Kynaston Pearson, Francis J B ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CITY UNIVERSITY   (United Kingdom)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; METHOTREXATE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANAPHYLAXIS; CONGESTIVE HEART FAILURE; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SHORT FORM 36; SYSTEMATIC REVIEW; TUBERCULOSIS; URINARY TRACT INFECTION; ARTHRITIS, RHEUMATOID; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; METHOTREXATE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942744693     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007649.pub3     Document Type: Review

References (163)

1. Anonymous Assesment report for Cimzia. Procedure No EMEA/H/C/001037. www.emea.europa.eu/humandocs/PDFs/EPAR/cimzia/H-1037-en6.pd. London, 2009:1-47. [: Procedure No.EMEA/H/C/001037]
2. Emery P, Smolen J, Choy E, et al.CDP870 a novel, humanised tumour necrosis factor alpha inhibitor improves HRQOL. Late breaking abstract. European League Against Rheumatism Annual Conference. 2002.
3. Keystone E, Choy E, Kalden J, Klareskog, Sany J, Smolen J, et al.CDP870, A novel pegylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA). Abstract to Rheumatology annual scientific meeting [abstract # LB-3]. 2001.
4. Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) 2012;51:1226-34.
5. UCB Clinical Study Summary Study No.: CDP870-014. http://www.clinicalstudyresults.org/documents/company-study_4348_0.pdf 2008.
6. Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN). http://clinicaltrials.gov/ct2/show/results/NCT00674362?term=NCT00674362&rank=1 2013.
7. Smolen JS, Emery P, Ferracioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases 2014:doi:10.1136/annrheumdis-2013-204632.
8. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41(10):1133-7.
9. Fleischmann D, Mason D, Cohen S. Efficacy and safety of certolizumab pegol monotherapy in patients with rheumatoid arthritis failing previous DMARD therapy. Annals of the Rheumatic Diseases 2007;66 Suppl II:169.
10. Fleischmann R, Keininger DL, Tahiri-Fitzgerald E, Mease P. Certolizumab pegol monotherapy 400mg every 4 weeks improves physical functioning and reduces pain in patients with rheumatoid arthritis Who have previously failed DMARD therapy. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0148]. 2007.
11. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: the FAST4WARDstudy. Annals of the Rheumatic Diseases 2009;68:805-11.
12. Keystone E, Mason D, Roy Fleischmann R. Certolizumab pegol 400 mg every 4 weeks as monotherapy rapidly reduces disease activity in active rheumatoid arthritis. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #277]. 2007.
13. Strand V, Brown M, Purcaru O, Richard L. Certolizumab pegol monotherapy improves productivity in patients with active rheumatoid arthritis: results from a phase III randomized controlled trial. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0478]. 2007.
14. Strand V, Keininger D, Tahiri-Fitzgerald E, Fleischmann R. Certolizumab pegol monotherapy 400mg every 4 weeks improves health-related quality of life and relieves fatigue in patients with rheumatoid arthritis who have previously failed DMARD therapy. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0205]. 2007.
15. Yamamoto K. Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA). http://clinicaltrials.gov/show/NCT00791921 2012.
16. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al.AB0469. Improved physical function, pain, and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients without methotrexate co-administration:results from the Hikari study. Annals of the Rheumaic Diseases 2013;71 Suppl 3:664.
17. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al. Certolizumab pegol improved physical function and heath related quality of life in patients with active rheumatoid arthritis who could not be treated with methotrexate: results form HIKARI study. Modern Rheumatology 2012;22 Suppl ll:S83.
18. Saito K. Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA). http://clinicaltrials.gov/ct2/show/study/NCT00791999?term=NCT00791999&rank=1 2012.
19. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern Rheumatology 2013 Dec 9 [Epub ahead of print]:doi:10.3109/14397595.2013.864224.
20. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al.AB0468 Improved physical function, pain, and health related quality of life with certolizumab pegol in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the JRapid study. Annals of the Rheumatic Diseases 2013;71 Suppl 3:664. [DOI: 10.1136/annrheumdis-2012-eular.468]
21. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al. Certolizumab pegol improved physical function and heath related quality of life in patients with active Rheumatoid Arthritis despite treatment with methotrexate: results form the JRAPID study. Modern Rheumatology 2012;22 Suppl ll:S83.
22. Eun Young Cho. A study of CDP870 as add-on medication to methotrexate (MTX) in patients with rheumatoid arthritis. http://clinicaltrials.gov/ct2/show/study/NCT00993317 2012.
23. Marc de Longueville on behalf of the UCB Team. Eun Young Cho. A study of CDP870 as add-on medication to methotrexate (MTX) in patients with rheumatoid arthritis. private e-mail 2012.
24. Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis and Rheumatism 2011;63:2203-8.
25. Curtis JR, Luijtens K, Kavanaugh A. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Research (Hoboken) 2012;64:658-67.
26. Keystone E, Heijde D, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism 2008;58:3319-29.
27. Keystone E, Mason D, Combe B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: 1-year results from the RAPID 1 study. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #700]. 2007.
28. Strand V, Keininger DL, Tahiri-Fizgerald E. Certolizumab pegol results in clinically meaningful improvements in physical function and health-related quality of life in patients with active rheumatoid arthritis despite treatment with methotrexate. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #946]. 2007.
29. Strand V, Mease P, Burmester G, Nikai E, Coteur G, Vollenhoven R, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research & Therapy 2009; Vol. 11:R170.
30. UCB Preliminary results suggest certolizumab pegol plus methotrexate is effective in reducing signs and symptoms of rheumatoid arthritis in patients refractory to methotrexate. Results from the RAPID 1 Study. Abstract number: OPO016. EULAR 2007. 2007.
31. van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. Journal of Rheumatology 2012;39:1326-33.
32. van der Heijde D, Strand V, Keystone E, Landewé R. Inhibition of Radiographic Progression by Lyophilized certolizumab Pegol Added to Methotrexate in Comparison with Methotrexate Alone in Patients with Rheumatoid Arthritis: The RAPID 1 Trial. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #940]. 2007.
33. van der Heijde D, Weinblatt M, Landewe R Goel N, Wells A, Fleischmann R. Inhibition of progression of structural damage by week 16 with certolizumab pegol: Results from the RAPID trials. Arthritis and Rheumatism 2008;58(9 Suppl):529-30 .
34. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis and Rheumatism 2009;61:1592-600.
35. Landewé R, Strand V, Smolen J, Van der Heijde D. Liquid formulation certolizumab pegol with methotrexate decreases progression of structural joint damage in rheumatoid arthritis patients: the RAPID 2 study. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #696]. 2007.
36. Mease P, Mason D, Kavanaugh A, Smolen J. Efficacy and rapid response of certolizumab pegol liquid formulation in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study. Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #941]. 2007.
37. Schiff M, Keininger DL, Tahiri-Fitzgerald E. Certolizumab pegol added onto methotrexate improves physical functioning and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate: data from rapid 2. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0200]. 2007.
38. Smolen J, Brzezicki J, Mason D, Kavanaugh A. Efficacy and safety of certolizumab pegol in combination with methotrexate (mtx) in patients with active rheumatoid arthritis despite MTX therapy: results from the rapid 2 study. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0202]. 2007.
39. Smolen JS, Landewe RB, Mease PJ, BrzezickiJ, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases 2009;68:797-804.
40. Strand V, Keininger DL, Tahiri-Fizgerald E. Certolizumab pegol results in clinically meaningful improvements in physical function and health-related quality of life in patients with active rheumatoid arthritis despite treatment with methotrexate. Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0335]. 2007.
41. Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Annals of the Rheumatic Diseases 2011;70:996-1002.
42. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012;51:2204-14.
43. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PloS ONE 2012;7:e30275.
44. Alten R, Fleischmann R, van Vollenhoven R, Vencovsky J, Davies O, Stach C, et al. Long term tolerability and efficacy of a 4-week-administration of certolizumab pegol as monotherapy and combination therapie in rheumatoid arthritis-5-year-data of an open extension study. Zeitschrift Fur Rheumatologie 2013;72:111.
45. Andreakos E. Targeting cytokines in autoimmunity: New approaches, new promise. Expert Opinion on Biological Therapy 2003;3(3):435-47.
46. Anonymous CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade. Drugs in R&D 2003;4:174-8.
47. Audrey P, Nahema I, Thomas B, Christophe R, Thierry S. Clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequate responders to methotrexate: A metanalysis. Arthritis and Rheumatism 2010;62:2267.
48. Bain B, Brazil M. Adalimumab. Nature Reviews. Drug Discovery 2003;2(9):693-4.
49. Bansback N, Brennan A, Anis AH. A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research 2005;5(5):519-29.
50. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: Focus on certolizumab pegol. International Journal of Nanomedicine 2007;2(1):3-7.
51. Baugh JA, Bucala R. Mechanisms for modulating TNFα in immune and inflammatory disease. Current Opinion in Drug Discovery and Development 2001;4(5):635-50.
52. Bayes M, RabassedaX, Prous JR. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology 2006;28(1):719-40.
53. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nature Clinical Practice. Gastroenterology & Hepatology 2006;3:220-8.
54. Chikanza IC, Kuis W, Heijnen CJ. The influence of the hormonal system on pediatric rheumatic diseases. Rheumatic Diseases Clinics of North America 2000;26:911-25.
55. Chikanza IC, Grossman AB. Reciprocal interactions between the neuroendocrine and immune systems during inflammation. Rheumatic Diseases Clinics of North America 2000;26:693-711.
56. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 2013;73:75-97.
57. Dosing Flexibility Study in Patients With Rheumatoid Arthritis (DoseFlex). http://clinicaltrials.gov/ct2/show/results/NCT00580840.
58. Evans R. Anti-Arthritic Agents - SMi Conference: Trapping cytokines 28-29 April 2003, London, UK. Drugs 2003;6(6):548-51.
59. Fanet-Goguet M, Martin S, Fernandez C, Fautrel B, Bourgeois P. Focus on biological agents in rheumatoid arthritis: Newer treatments and therapeutic strategies. Therapie 2004;59(4):451-61.
60. Fleischmann RM. Is there a need for new therapies for rheumatoid arthritis?. Journal of Rheumatology 2005;32(73 Suppl):3-7.
61. Fleischmann R, van Vollenhoven R, Vencovsky J, Alten R, Davies O, Stach C, et al.Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study. Annals of the Rheumatic Diseases 2013;72:435.
62. Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 2002;2(2):135-49.
63. Garber K. First-in-class biologic to enter rheumatoid arthritis fray. Nature Biotechnology 2005;23(11):1323-4.
64. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. Journal of Clinical Rheumatology 2005;11(3 Suppl):45-54.
65. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clinical and Experimental Immunology 2005;140(2):195-204.
66. Graninger W, Smolen J. Treatment of rheumatoid arthritis by TNF-blocking agents. International Archives of Allergy and Immunology 2002;127(1):10-4.
67. Ingham M, Carter C. Meta-analysis and biologics comparing apples to apples: An example using radiographic outcomes in rheumatoid arthritis. Arthritis and Rheumatism 2010;62:76.
68. Janssen KJ, Medic G, Broglio K, Bergman G, Berry S, Sabater FJ, et al. Comparing the efficacy and safety of biologics for the treatment of rheumatoid arthritis patients: A network meta-analysis. Value in Health 2012;15 (7):A439.
69. Kathmann W. Early and aggressive treatment of rheumatoid arthritis. Deutsche Medizinische Wochenschrift 2005;130 Suppl 1(Report):58-9.
70. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opinion on Biological Therapy 2005;5:601-6.
71. Kavanaugh A, Smolen JS, Emery P, Keystone E, Strand V, Purcaru O, et al.Long-term benefits over more than 4 years of certolizumab pegol combination therapy on workplace and household productivity, and participation in social activities in rheumatoid arthritis: Results from the open-label extension study. Value in Health 2013;16:A570.
72. Kavanaugh A, Smolen J, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place. Productivity and social activities in patients with active rheumatoid arthritis. Arthritis and Rheumatism 2009;61:1592-600.
73. Keystone E, Landewe R, van Vollenhoven R, Combe B, Strand V, Mease P, et al.5-Year results from the RAPID 1 trial and open-label extension: long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 2013;72:A228-9. [10.1136/annrheumdis-2013-203695. [Epub ahead of print]]
74. Keystone E, Landewe R, van Vollenhoven R, Combe B, Strand V, Mease P, et al.Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Annals of the Rheumatic Diseases 2013;65:S988-9. [PUBMED: 23918037]
75. Kochbati S, Boussema F, Ben Miled M, Ktari S, Daoud L, Ben Rhouma S, et al. The TNF alfa in the treatment of rheumatoid arthritis. Tunisie Medicale 2004;82(10):893-904.
76. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. Journal of Rheumatology 2011;38:835-45.
77. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: A multiple-treatment Bayesian metaanalysis. Journal of Rheumatology 2011;38:835-45.
78. Le Blay P, Mouterde G, Barnetche T, Combe BG. Risk of malignancy during anti-TNF alfa therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis of registries, long-term extension studies and randomized controlled trials. Arthritis and Rheumatism 2010;62:408.
79. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: Metaanalysis of randomized controlled trials. Journal of Rheumatology 2012;39:712-5.
80. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. Journal of Rheumatology 2012;39:712-5.
81. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:896-908.
82. Mealy NE, Bayes M. Treatment of gastrointestinal disorders: certolizumab pegol. Drugs of the Future 2005;30(6):600-1.
83. Mok CC, Mak A. Therapeutic advances in rheumatoid arthritis. APLAR Journal of Rheumatology 2004;7(1):62-70.
84. Moulis G, Sommet A, Bene J, Montastruc F, Sailler L, Montastruc JL, et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: A meta-analysis with intention to treat and per protocol analyses. PLoS ONE 2012;7:e48991.
85. Mount C, Featherstone J. Rheumatoid arthritis market. Nature Reviews. Drug Discovery 2005;4(1):11-2.
86. A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis. http://clinicaltrials.gov/ct2/show/NCT00160641?term=NCT00160641&rank=1 2013.
87. Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis. http://clinicaltrials.gov/ct2/show/NCT00160693.
88. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford) 2012;51:1628-38.
89. van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. Journal of Rheumatology 2012;39:1326-33.
90. Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) (Dose Flex II). http://clinicaltrials.gov/ct2/show/NCT00753454?term=NCT00753454&rank=1 2012.
91. Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN 2). http://clinicaltrials.gov/ct2/show/NCT00843778?term=NCT00843778&rank=1 2013.
92. Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines. http://clinicaltrials.gov/ct2/show/results/NCT00993668?term=NCT00993668&rank=1 2012.
93. Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discovery Today 2003;8(18):845-51.
94. Paleolog E. The therapeutic potential of TNF-α blockade in rheumatoid arthritis. Expert Opinion on Investigational Drugs 2003;12(7):1087-95.
95. Pearce GJ, Chikanza LC. Targeting tumour necrosis factor in the treatment of rheumatoid arthritis. BioDrugs 2001;15(3):139-49.
96. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint, Bone, Spine 2013;80:386-92.
97. Rose-John S, Schooltink H. CDP-870. Celltech/Pfizer. Current Opinion in Investigational Drugs 2003;4(1472-4472 (Print), 5):588-92.
98. Russo C, Polosa R. TNF-α as a promising therapeutic target in chronic asthma: A lesson from rheumatoid arthritis. Clinical Science 2005;109(2):135-42.
99. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Practice & Research. Clinical Gastroenterology 2003;17(1):105-17.
100. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. The New England Journal Medicine 2007;357:239-50.
101. Smolen JS, Emery P, Ferraccioli G, Samborski W, Berenbaum F, Davies O, et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study. Annals of the Rheumatic Disease 2013;71 Suppl 3:361.
102. Sorbera LA, Leeson PA. Certolizumab pegol: Treatment of rheumatoid arthritis treatment of Crohn's disease human anti-TNF-(alpha) monoclonal antibody. Drugs of the Future 2005;30(11):1087-91.
103. Takeuchi T, Amano K, Kameda H, Abe T. Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. Allergology International 2005;54(2):191-202.
104. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, et al.Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology 2013:DOI:10.3109/14397595.2013.865822.
105. Taylor PC. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Current Pharmaceutical Design 2003;9(14):1095-106.
106. Taylor PC. Anti-TNFα therapy for rheumatoid arthritis: An update. Internal Medicine 2003;42(1):15-20.
107. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opinion on Pharmacotherapy 2004;5(3):581-94.
108. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opinion on Pharmacotherapy 2007;8:2089-107.
109. Wang Y, Zhu R, Sun J, Su Z, Davis JC, Mandema JW, et al.Model-based meta-analysis in rheumatoid arthritis: Correlations between short-term and long-term treatment effects. Clinical Pharmacology and Therapeutics 2013;93:S101.
110. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al. Improved physical function, pain and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate. Results from the JRapid Study. Annals of the Rheumatic Diseases 2013;72 Suppl 3:664.
111. Yamanaka H, Yamamoto K, Takeuchi T, Ishiguro N, Tanaka Y, Eguchi K, et al. Improved physical function, pain and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients without methotrexate co-administration. Results from the HIKARI Study. Annals of the Rheumatic Diseases 2013;72 Suppl 3:664.
112. Zhu R, Wang Y, Sun J, Su Z, Davis JC, Mandema JW, et al.Model-based meta-analysis in rheumatoid arthritis: Correlation of DAS28 and ACR50 treatment effects. Clinical Pharmacology and Therapeutics 2013;93:S101.
113. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: Targeting cytokines. Annals of the New York Academy of Sciences 2005;1051:716-29.
114. Long-term Treatment Study of CDP870 Without Coadministration of MTX in Japanese Rheumatoid Arthritis (RA) Patients. Ongoing study Mar 2009; expected completed date: Mar 2012.
115. Long-term Treatment Study of CDP870 as Add-on Medication to MTX in Japanese Rheumatoid Arthritis (RA) Patients. Ongoing study Mar 2009; expected completion Mar 2011.
116. A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Early MTX-naive Rheumatoid Arthritis Patients With Poor Prognosis. Ongoing study October 2011.
117. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-24.
118. Barton A, Worthington J. Genetic susceptibility to rheumatoid arthritis: an emerging picture. Arthritis and Rheumatism 2009;61:1441-6.
119. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004 2004;170:477-80.
120. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, Tugwell P. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
121. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
122. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation 2008;118:3537-45.
123. Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Annals of the Rheumatic Diseases 2013:doi: 10.1136/annrheumdis-2013-203660. [Epub ahead of print]. [DOI: 10.1136/annrheumdis-2013-203660]
124. Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002;41:88-95.
125. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006; Vol. 10, issue 42:1-235.
126. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society of Rheumatology Biologics Register. Arthritis & Rheumatism 2007;56:2905-12.
127. Doeglas D, Suurmeijer T, Krol B, Sanderman R, van Leeuwen M, van Rijswijk M. Work disability in early rheumatoid arthritis. Annals of the Rheumatic Diseases 1995;54:455-60.
128. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis and Rheumatism 2002;46:625-31.
129. Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clinical and Experimental Immunology 2005;143:1-5.
130. Anonymous Assesment report for Cimzia. Procedure No EMEA/H/C/001037. www.emea.europa.eu/humandocs/PDFs/EPAR/cimzia/H-1037-en6.pd. London, 2009:1-47. [: Procedure No.EMEA/H/C/001037]
131. Center for Drug Evaluation and Research. Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124185.htm (accessed 7 Jul 2014).
132. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology, European League Against Rheumatism. Provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism 2011;63:573-86.
133. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94:130-6.
134. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010;49:1900-10.
135. Higgins JPL, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 201]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
136. Jobanputra P, Maggs F, Deeming A, Carruthers D, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2012;2:e001395.
137. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford) 2012;51:1628-38.
138. Laird NM, Wang F. Estimating rates of change in randomized clinical trials. Controlled Clinical Trials 1990;11:405-19.
139. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. The New England Journal of Medicine 1988;318:1728-33.
140. Lethaby A, Lopez-OlivoMA, Maxwell L, Burls A, Tugwell P, WellsGA Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD004525.pub2]
141. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
142. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD000957.pub2]
143. Meune C, Touze E, Trinquart L, Allanmore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309-13.
144. Navarro-Millan I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and non antitumor necrosis factor biologics for rheumatoid arthritis. Current Opinion in Rheumatology 2013;25:384-90.
145. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
146. UCB Certolizumab pegol (CIMZIA©) for the treatment of rheumatoid arthritis. Single technology appraisal (STA) manufacturer submission to NICE. NICE June 22nd 2009:1-180.
147. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al.FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis and Rheumatology 2005;52:36-4.
148. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
149. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341]
150. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2]
151. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al.2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research 2012;64:625-39.
152. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases 2010;69:631-7.
153. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases 2014;73(3):492-509.
154. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999;18:2693-708.
155. Turesson C. Extra-articular rheumatoid arthritis. Current Opinion in Rheumatology 2013;23:360-6.
156. Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Annals of the Rheumatic Diseases 2014 May 1:DOI:10.1136/annrheumdis-2013-205079. [DOI: 10.1136/annrheumdis-2013-205079; PUBMED: 24794149]
157. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association 2006;94:41-7.
158. Wong SS, Wilczynski NL, Haynes RB. Optimal CINAHL search strategies for identifying therapy studies and review articles. Journal of Nursing Scholarship 2006;38:194-9.
159. Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF. West Midlands Rheumatology Services and Training Committee. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology (Oxford) 2003;42:856-9.
160. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early RA study (ERAS). Rheumatology 2000;39:603-11.
161. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007;46:350-7.
162. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal American Medical Association 1991;266:93-8.
163. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, Fry-Smith A. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD007649.pub2]